Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of itepekimab in moderate-to-severe COPD
MOH_2021-04-22_009914Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of itepekimab in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Sanofi. Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Started Feb 2021; status: recruiting.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2021-04-22_009914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-22_009914.